Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia
Frontiers in Oncology · 07.09.2023 · 13
DOI: 10.3389/fonc.2023.1244280 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 07.09.2023. Verfasst von Lili Feng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical Univ…. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Chemoresistance often complicates the management of cancer, as noted in the instance of acute myeloid leukemia (AML). Mitochondrial function is considered important for the viability of AML blasts and appears to also modulate chemoresistance. As mitochondrial metabolism is aberrant in AML, any distinct pathways could be directly targeted to impact both cell viability and chemoresistance. Therefore, identifying and targeting those precise rogue elements of mitochondrial metabolism could be a valid therapeutic strategy in leukemia. Here, we review the evidence for abnormalities in mitochondria metabolic processes in AML cells, that likely impact chemoresistance. We further address several therapeutic approaches targeting isocitrate dehydrogenase 2 (IDH2), CD39, nicotinamide phosphoribosyl transferase (NAMPT), electron transport chain (ETC) complex in AML and also consider the roles of mesenchymal stromal cells. We propose the term “mitotherapy” to collectively refer to such regimens that attempt to override mitochondria-mediated metabolic reprogramming, as used by cancer cells. Mounting evidence suggests that mitotherapy could provide a complementary strategy to overcome chemoresistance in liquid cancers, as well as in solid tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Center for Inflammation Research, Department of Anesthesia, Critical Care & Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
- Antagen Institute for Biomedical Research, Canton, MA, United States.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Medicine, Division of Gastroenterology/Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
Zitieren
APA
Feng, L., Zhang, P. Y., Gao, W., Yu, J., & Robson, S. C. (2023). Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1244280
Vancouver
Feng L, Zhang PY, Gao W, Yu J, Robson SC. Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1244280
BibTeX
@article{Feng2023,
author = {Feng, Lili and Zhang, Philip Y and Gao, Wenda and Yu, Jinming and Robson, Simon C},
title = {Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1244280}
}
EUVIMED